Search clinical trials for: PD-1 plus Dasatinib

Total 1204 results

The Affiliated Hospital of Qingdao University

Unknown

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

NSCLC Stage IV | PD-1 | ARID1A

China
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial...

Active, not recruiting

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

Colorectal Cancer | Microsatellite Instability High

China
Capital Medical University
Duke University

Completed

Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors

Neoplasms

China
Capital Medical University
Duke University; Geneplus-Beijing Co. Ltd.

Completed

Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC

Neoplasms | Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

Sarcoma

China
Navy General Hospital, Beijing

Recruiting

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Refractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin Lymphoma

China
Shandong Cancer Hospital and Institute
BeiGene

Active, not recruiting

A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma (Notable-HCC)

Hepatocellular Carcinoma

China
Tongji Hospital
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma (CCGLC-008)

Hepatocellular Carcinoma Non-resectable

China
Sun Yat-sen University

Recruiting

Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma

Neoadjuvant Therapy | Apatinib | Carilizumab | Recurrent High-Grade Glioma

China
Chen Xiaoping

Not yet recruiting

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

HCC
Neuroscience Research Australia
Michael J. Fox Foundation for Parkinson's Research; Shake it up Australia Foundation and other collaborators

Completed

The WalkingTall Study: Comparing WalkingTall With Parkinson's Disease (WalkingTall-PD) With Mobility-plus to Reduce Falls and Improve Mobility. (WalkingTall-PD)

Parkinson Disease

Australia
Fudan University

Recruiting

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Advanced Thyroid Cancer Patients Who Received Target Therapy

China
Wan-Guang Zhang
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-001)

Hepatocellular Carcinoma Non-resectable

China
Wei Jiang
Wuzhou Red Cross Hospital; Laibin People's Hospital; Guangxi Naxishan Hospital; People's Hospital of Lingshan

Completed

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
University of California, San Francisco
Genentech, Inc.

Completed

Effects of Gastric pH on the Pharmacokinetics of Dasatinib

Healthy

United States
Shanghai Zhongshan Hospital

Recruiting

Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Neoadjuvant Chemoimmunotherapy

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma (SHR-1210)

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer

Gastric Cancer

China
Shanghai Zhongshan Hospital

Recruiting

Gut Microbiota and Cancer Immunotherapy Response

Non-Small Cell Lung Cancer

China
TruDiagnostic

Active, not recruiting

Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging

Aging

United States
Peking University People's Hospital

Not yet recruiting

Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma (NICLA)

Adenocarcinoma of Esophagogastric Junction

China
RWJ Barnabas Health at Jersey City Medical Center

Unknown

Tumor Grade Determines PD-1/PDL-1 Expression

Ovarian Cancer | Endometrial Cancer

United States
Tianjin Medical University Cancer Institute and...

Completed

Chemotherapy Combined With Apatinib and PD-1 Antibody

Gastric Cancer

China
Fudan University

Recruiting

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

Carcinosarcoma | Sarcomatoid Carcinoma | PD-1 Immunotherapy | VEGFR-TKI

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Triple Negative Breast Cancer

China
Peking University

Not yet recruiting

Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ

Gastroesophageal Junction Cancer | Chemoradiotherapy | PD-1
The First Affiliated Hospital of Guangdong Pharmaceutical...
University of Technology, Sydney; Guangzhou Anjie Biomedical Technology Co....

Unknown

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Non-small Cell Lung Cancer | Lung Neoplasm Malignant

China
University of Colorado, Denver
National Cancer Institute (NCI); Cancer League of Colorado

Withdrawn

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Colorectal Cancer | Microsatellite Instability High | Mismatch Repair Deficiency

United States
Tongji Hospital
National Natural Science Foundation of China

Recruiting

Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study (NICCE)

Esophageal Squamous Cell Carcinoma | Neoadjuvant Therapies

China
Sinocelltech Ltd.

Unknown

Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma (CCGLC-009)

Cholangiocarcinoma Non-resectable

China
Centre Leon Berard
NETRIS Pharma

Recruiting

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies (IMMUNONET)

Advanced Solid Tumors | Metastatic Solid Tumors

France
Thomas Marron

Recruiting

Dupilumab_Metastatic NSCLC

Metastatic Non-small Cell Lung Cancer

United States
Tongji University

Recruiting

A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

NSCLC, Stage IIIA | EGF-R Negative Non-Small Cell Lung Cancer | ALK Negative NSCLC

China
Shanghai Zhongshan Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma (Neo-PLANET)

Gastric Adenocarcinoma

China
Instituto Nacional de Cancerologia de Mexico

Unknown

Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients

Non-Small Cell Lung Cancer

Mexico
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Nasopharyngeal Carcinoma | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
China Medical University, China

Recruiting

PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

Gastric Cancer | AFP

China
Yongchang Zhang

Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC

China
Lei Li

Completed

First-line Chemotherapy for Recurrent Cervical Cancer

Chemotherapy | Recurrent Cervical Carcinoma | Apatinib | Targeted Therapy | Persistent Advanced Cervical Carcinoma | Vascular Endothelial Growth Factor 2 Inhibitor

China
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma (IMplus)

Head and Neck Squamous Cell Carcinoma

China
Zhongnan Hospital

Recruiting

Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Lung Cancer

China
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
Shanghai Jiao Tong University School of Medicine

Recruiting

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

Oral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant Therapy | Anti-VEGFR

China
Fujian Cancer Hospital

Unknown

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Advanced Gastric Adenocarcinoma

China
Liang Peng
Guangzhou Virotech Pharmaceutical Co., Ltd.

Unknown

IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC

Advanced/Metastatic Hepatocellular Carcinoma
CureVac
Syneos Health; Cromos Pharma LLC

Active, not recruiting

Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

Carcinoma, Adenoid Cystic | Melanoma (Skin) | Squamous Cell Carcinoma of the Skin | Carcinoma, Squamous Cell of Head and Neck

Spain, France, Austria, Germany, Russian Federation
Adanate, Inc

Recruiting

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

Solid Tumor, Adult

United States

Search clinical trials for: PD-1 plus Dasatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations